U26. NMR: Biomedical Applications II

U26. NMR: Biomedical Applications II

• Scientific Director: Prof. Ramon Martinez Máñez  rmaez@qim.upv.es
• Scientific Coordinator: Dr. Salvador Gil salvador.gil@uv.es
• Entities: Universitat de Valencia (UV)
• Address: C/Dr. Moliner, 50, Edificico Investigación, 1º Pl., 46100, Valencia, Spain
• Phone: +34 963877343
• Tel Prof. Martínez: +34 963877343 ; Tel Dr. Gil : +34 963543135
• Web: UV

U26. Sample preparation lab

U26. DRX-600 Bruker NM R equipment (14T) with autosampler

U26. DRX-600 Bruker NM R equipment (14T) with refrigerated autosampler

Description

Located in the Faculty of Medicine of the University of Valencia (UV) has a laboratory with a NMR (14T) for acquiring unique metabolic profiles of biofluids, cell lines and tissues. This Unit is coordinated by Dr. Ramón Martínez Máñez, PI of the Applied Molecular Chemistry Group of the Universidad Politécnica de Valencia, together with Dr. Salvador Gil, Director of the Central Service for Experimental Research (SCSIE).

News U26

23 Jun

Discover the latest Biomedical Imaging and Metabolomics equipment at NANBIOSIS platforms

Seminar on imaging and metabolomics platforms at UV, featuring NANBIOSIS equipment and recent biomedical research applications. Valencia, June 2025 — Researchers and clinicians interested in cutting-edge preclinical imaging and metabolomics technologies are invited to attend the upcoming seminar “Biomedical and Metabolomic Imaging Section: Equipment and Applications”, taking place on Friday, June 27, 2025, at 13:00, in Seminar Room D, Faculty of Medicine and Dentistry, Universitat de València. The seminar will be delivered by Mustafa Ezzeddin Ayoub (“Musta”), technical expert from the Biomedical and Metabolomic Imaging Section at the University Clinical Hospital of Valencia (UCIM). The session will provide a comprehensiv[...]

04 Apr

Showcase of Nanomedicine Research at CIBERES Infectious Diseases Meeting

NANBIOSIS joins CIBERES meeting to foster collaboration in nanomedicine and infectious disease research, showcasing capabilities and innovations. Zaragoza, march 2025. Last week, the CIBERES Infectious Diseases Program Meeting took place at the Centro de Investigación Biomédica de Aragón (CIBA), bringing together leading experts in respiratory infectious diseases to explore new research collaborations. The event featured presentations from various CIBER research areas, including CIBERINFEC, CIBERESP, and CIBER-BBN, highlighting potential synergies in tackling infectious diseases. NANBIOSIS Director Ramón Martínez Máñez introduced the nanomedicine research lines, emphasizing the support on biomedical innovation. Other key speakers included Roberto Hornero, who presented the Bioengineering researc[...]

13 Feb

New European Project “SmILE” Aims to Revolutionize Musculoskeletal Disease Management

SmILE develops smart implants and digital health solutions to prevent and manage musculoskeletal diseases, enhancing patient care and independence. Lübeck, February 2025. The European project “SmILE” has been launched to provide innovative solutions for reducing the burden of musculoskeletal non-communicable diseases (MSK-NCDs) among the elderly through preventive measures and early interventions. Supported by the Horizon Europe programme and the Swiss State Secretariat for Education, Research and Innovation (SERI), this collaborative initiative brings together 25 institutions from 12 European countries with a budget of €19.9 million, plus an additional €760K from SERI, over five years. Addressing the Challenges of MSK-NCDs Wit[...]

17 Dec

NANBIOSIS enables new breakthrough study on Carotid Plaque vulnerability

NANBIOSIS Unit 26 identifies biomarkers of carotid plaque vulnerability, aiding stroke prevention with advanced NMR metabolomics and collaborative innovation. Valencia, december 2024. NANBIOSIS Unit 26, one of our NMR Biomedical Applications Platforms, has once again demonstrated its essential role in cutting-edge medical research. A recent study, conducted in collaboration with multiple research institutions, identified key biomarkers associated with carotid plaque vulnerability, a critical factor in stroke risk. A Collaborative Effort in Cardiovascular Research The study analyzed metabolic differences between symptomatic and asymptomatic carotid plaques, aiming to predict which plaques are at higher risk of rupture. Using advanced nuclear magnetic resonanc[...]

07 Nov

European Partnership Opens a New Era in Rare Disease Research

The European Rare Diseases Research Alliance (ERDERA) kicked off last month, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond. Paris, october 2024. The European Rare Diseases Research Alliance (ERDERA), a new initiative under Horizon Europe, has officially launched with an ambitious mission to improve the lives of 30 million people affected by rare diseases across Europe and beyond. Backed by a budget of €380 million, ERDERA brings together more than 170 organizations from the public and private sectors, led by the National Institut[...]

18 Oct

Prof. Ramón Martínez, Director of NANBIOSIS, has been awarded the Spanish National Research Prize

Prof. Ramón Martínez Máñez wins the 2024 National Research Award for his work in nanotechnology, drug delivery systems, and biomedical, environmental sensors. Valencia, october 2024. Prof. Martínez Máñez has been honored with the “Juan de la Cierva” National Research Award for the impact of his scientific career and its transfer in the field of chemistry, specifically in nanotechnology for controlled release systems and their use in sensors for medical, environmental, and agricultural applications. The evaluators also highlighted the high number of patents obtained and licensed by the awardee and emphasized the number of companies he has created, one of whic[...]

25 Oct

Ramón Martínez Máñez, Scientific Director of NANBIOSIS U26 obtains an ERC Advanced Grant

Ramón Martínez Máñez, researcher at the Polytechnic University of Valencia (UPV) and scientific director of the Bioengineering, Biomaterials and Nanomedicine area of ​​the CIBER (CIBER-BBN) and NANBIOSIS U26, has obtained an ERC Advanced Grant –the most prestigious grant from the European Research Council– endowed with 2.5 million euros for the development of the EDISON project (Engineered Particles for Chemical Communication). This project focuses on the field of chemical or molecular communication. Its objective is the study, development and application of nanoparticles that are capable of communicating with each other and whose application would represent a revolution in the field of[...]

16 Aug

The University of Valencia among the 300 best universities in the world, hosting NANBIOSIS U26 of CIBER-BBN on RNM for Biomedical Applications

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the University of Valencia among the elite of the 300 best universities in the world and the second of the Spanish universities. This indicator organizes up to 20,000 university centers worldwide,based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings The NANBIOSIS U26 NMR: Biomedical Applications II created by CIBER-BBN is hosted by the University of Valencia is led by Prof. Ramón Martínez Ma´ñez and Prof Salvador Gil Grau[...]